When researching hyaluronic acid (HA) dermal fillers, prospective patients frequently ask a straightforward question: "How long does Juvéderm last?"
Med spa marketing and consumer articles often give a broad, oversimplified answer—claiming that "Juvéderm lasts 12 to 18 months" or repeating manufacturer headlines that "Voluma lasts up to 2 years."
The evidence-based clinical reality is that there is no single "Juvéderm duration." In the United States the collection sits on two PMA numbers—P050047 (Hylacross / Ultra family, original approval 2 June 2006) and P110033 (Vycross / Voluma family, original approval 22 October 2013)—with later supplements for new areas and products. Supplements are not nine separate PMAs. Longevity is product- and area-specific, and manufacturer "up to" statements are ceilings after initial treatment plus optional touch-up, not medians for a single unretreated syringe.
A syringe of Juvéderm Voluma in the deep malar cheek behaves completely differently from Voluma in the chin, Volbella in the lips, Vollure in the nasolabial folds, or Skinvive microdroplets in the mid-dermis. For product-selection comparisons against competitors, see our analysis of Juvéderm vs. Restylane; for lip-specific longevity across all brands, see how long lip filler lasts. This guide analyzes the official Summary of Safety and Effectiveness Data (SSED) documents from FDA approvals to map the exact clinical persistence of each product.
[Juvéderm Family Regulatory & Persistence Map]
Product / Indication PMA & Decision Date Trial Efficacy Follow-Up & Responders Manufacturer "Up To"
───────────────────────── ─────────────────── ──────────────────────────────────────── ────────────────────
Voluma XC (Cheeks) P110033 (2013-10-22) M6: 85.6% | M12: 85.2% | M24: 67.1% (n=167)Up to 24 Months
Voluma XC (Chin) P110033/S047 (2020) M6: 56.3% | M12: 57.6% (n=125) Up to 12 Months
Voluma XC (Temples) P110033/S070 (2023) M3: 80.4% | M13: 72.2% GAIS (n=113) Up to 13 Months
Volux XC (Jawline) P110033/S065 (2022) M6 ALJDS 69.0%; M12 subject GAIS 74.3% (104/140)
Vollure XC (Nasolabial) P110033/S020 (2017) M6: 93.2% | M12: 57.5% | M18: 59.4% (n=96)
Volbella XC (Lips) P110033/S018 (2016) M3: 80.3% | M6: 71.1% | M12: 61.8% (n=123)
Volbella XC (Under-Eye) P110033/S053 (2021) M3: 83.1% | M12: 73.4% (69/94)
Ultra XC (Lips) P050047/S044 (2015) M3: 79.1% | M12: 56.4% (n=101)
Skinvive (Cheek Smoothness) P110033/S059 (2023) M1: 96.2% (251/261 cheeks); 76.3% at M4
Direct Answer: Does Juvéderm Really Last 2 Years?
When evaluating Juvéderm duration claims:
- What "Up to 2 Years" actually means: The 2-year duration claim applies exclusively to Juvéderm Voluma XC injected into the deep cheek (malar/submalar zone). In the pivotal FDA trial (P110033), 67.1% of subjects remained clinical responders at Month 24.
- The "Optimal Treatment" requirement: Labeled "up to" claims follow initial injection plus an optional touch-up. Volumes are area-specific (temple SSED median 2.0 mL initial and 1.5 mL touch-up for both temples). A single conservative syringe without touch-up is not the trial design.
- Area-to-Area Differences: Voluma does not last 2 years in the chin or temples:
- Chin: Voluma XC is approved for chin augmentation (P110033/S047) with a labeled persistence of up to 1 year (57.6% responder rate at Month 12).
- Temples: Voluma XC is approved for temple hollowing (P110033/S070) with a labeled duration of up to 13 months (72.2% GAIS responder rate at Month 13).
- The Lip Duration Reality: Juvéderm in the lips (whether Ultra XC or Volbella XC) lasts 9 to 12 months, not 18 to 24 months. Constant dynamic movement from talking, chewing, and expression accelerates mechanical breakdown.
- Volbella is NOT Vollure: Clinic marketing frequently claims Volbella lasts 18 months. In FDA trials, Volbella lip fullness was 61.8% at 1 year. The 18-month duration belongs to Vollure XC in nasolabial folds (P110033/S020).
- Skinvive is NOT a volumizer: Skinvive (P110033/S059) is intradermal cheek smoothness. 96.2% (251/261) of treated cheeks were ACSS responders at Month 1; 76.3% (196/257) still were at 4 months; 15.7% (39/249) at 9 months. Manufacturer "up to 6 months" is a ceiling, not the Month 1 rate lasting half a year.
The Two Juvéderm PMA Families: Hylacross vs. Vycross
In the FDA CDRH Premarket Approval database (Class III medical devices under 21 CFR 878.3540, Product Code LMH), the Juvéderm collection is split into two distinct manufacturing lineages:
[The Two Juvéderm Regulatory Lineages]
PMA P050047 (ORIG: 2006-06-02) PMA P110033 (ORIG: 2013-10-22)
Hylacross (100 FDA PMA listing rows) Vycross (96 FDA PMA listing rows)
───────────────────────────────────── ──────────────────────────────────
• Juvéderm 24HV / 30 / 30HV (2006) • Juvéderm Voluma XC Cheeks (2013, ORIG)
• Juvéderm Ultra XC / Ultra Plus XC • Juvéderm Volbella XC Lips (2016, S018)
• Juvéderm Ultra XC Lips (2015, S044) • Juvéderm Vollure XC NLFs (2017, S020)
• Juvéderm Voluma XC Chin (2020, S047)
Characteristics: • Juvéderm Volbella XC Under-Eye (2021, S053)
• 100% High-Molecular-Weight HA • Juvéderm Volux XC Jawline (2022, S065)
• Higher water absorption / swelling • Skinvive by Juvéderm (2023, S059)
• Soft, plush volumetric projection • Juvéderm Voluma XC Temples (2023, S070)
• Typical duration: 6 to 12 months
Characteristics:
• 90% Low-MW + 10% High-MW HA Cross-Linking
• Tighter polymer matrix; minimal swelling
• Enhanced resistance to enzymatic degradation
• Typical duration: 6 to 24 months (by area)
Product-by-Product Analysis: SSED Denominators and Responder Curves
To understand how each Juvéderm formulation behaves over time, we must examine the specific Summary of Safety and Effectiveness Data (SSED) clinical trial endpoints submitted to the FDA:
1. Juvéderm Voluma XC — Cheeks (PMA P110033 ORIG, October 22, 2013)
- Indication: Deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related midface volume deficit in adults over 21.
- Clinical Trial Data: In the pivotal multicenter trial of 282 subjects evaluated on the 6-point Mid-Face Volume Deficit Scale (MFVDS):
- Month 6: 85.6% (178/208) treatment-group subjects were responders.
- Month 12: 85.2% (172/203) maintained responder status.
- Month 18: 71.5% (128/179) remained responders.
- Month 24: 67.1% (112/167) still demonstrated clinically meaningful improvement.
- Takeaway: Voluma in the midface is the only Juvéderm product with documented 2-year clinical persistence. However, at Month 24, one in three patients (32.9%) had returned toward baseline and required maintenance.
2. Juvéderm Voluma XC — Chin Augmentation (PMA P110033/S047, June 12, 2020)
- Indication: Deep subcutaneous or supraperiosteal injection for chin augmentation to improve the chin profile in adults over 21.
- Clinical Trial Data: Evaluated on the 5-point Allergan Chin Retraction Scale (ACRS):
- Month 6: 56.3% (71/126) were responders vs. 27.5% in the control group.
- Month 12: 57.6% (72/125) maintained responder status.
- Important subgroup finding: The SSED states that Fitzpatrick V/VI, males, and subjects aged 51.5 years and older did not meet the 50% responder-rate threshold (male treatment-group responder rate 46.7%). Satisfaction in those subgroups was still high. Do not import cheek 85% figures onto a chin in a man or in darker phototypes.
- Takeaway: Do not transfer 24-month cheek expectations to the chin. Chin Voluma is a 1-year product. For structural chin alternatives, see our guide to chin filler vs. surgical implants.
3. Juvéderm Voluma XC — Temples (PMA P110033/S070, October 6, 2023)
- Indication: Subcutaneous or supraperiosteal injection to improve moderate to severe temple hollowing in adults over 21.
- Clinical Trial Data: Evaluated on the Allergan Temple Hollowing Scale (ATHS):
- Month 3 Primary Endpoint: 80.4% (90.8/113 via multiple imputation) responder rate.
- Month 13 GAIS: 72.2% (investigator) and 78.9% (subject) rated temples improved or much improved.
- Correction Note: Our previous article on temple filler anatomy and safety erroneously cited PMA supplement
S059 March 2024. Official FDA records confirm Voluma temples was approved under P110033/S070 on October 6, 2023 (S059 is Skinvive). - Takeaway: Voluma in the temple region carries an FDA-supported clinical longevity of up to 13 months.
4. Juvéderm Volux XC — Jawline Definition (PMA P110033/S065, July 29, 2022)
- Indication: Subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over 21 with moderate to severe loss of jawline definition.
- Clinical Trial Data: Evaluated on the Allergan Loss of Jawline Definition Scale (ALJDS):
- Month 6 primary endpoint: 69.0% (108.3/157, multiple imputation) vs control 38.0% (18.6/49).
- Evaluating-investigator GAIS: 89.0% (130/146) improved at 6 months; 79.9% (107/134) at 12 months.
- Subject GAIS: 88.4% (129/146) at 6 months; 74.3% (104/140) at 12 months.
- Takeaway: Volux is formulated with Allergan's highest elasticity and cohesivity (high G' and G'') to mimic structural bone, lasting up to 12 months.
5. Juvéderm Vollure XC — Nasolabial Folds (PMA P110033/S020, March 17, 2017)
- Indication: Injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
- Clinical Trial Data: Evaluated on the nasolabial fold severity scale in the S020 SSED (NLFSS, ≥1-point improvement):
- Month 6: 93.2% (109/117) responder rate.
- Month 9: 84.6% (99/117).
- Month 12: 57.5% (65/113).
- Month 15: 61.7% (50/81).
- Month 18: 59.4% (57/96).
- Methodology Note: In the S020 trial, any nasolabial fold that received touch-up or asymmetry correction was categorized as a non-responder at subsequent timepoints. This conservative protocol explains why Month 18 (59.4%) shows robust persistence among unretreated folds.
- Takeaway: Vollure provides genuine 18-month durability in mid-facial dynamic folds. For fold alternatives, see nasolabial fold treatment options.
6. Juvéderm Volbella XC — Lips and Perioral Rhytids (PMA P110033/S018, May 31, 2016)
- Indication: Injection into the lips for lip augmentation and correction of perioral rhytids (vertical lip lines) in adults over 21.
- Clinical Trial Data: Evaluated on the Lip Fullness Scale (LFS):
- Month 3: 80.3% (122/152) achieved ≥1-point improvement.
- Month 6: 71.1% (106/149).
- Month 9: 65.1% (95/146).
- Month 12 (1 Year): 61.8% (76/123) maintained fullness; 58.5% (72/123) showed GAIS improvement.
- Takeaway: Volbella is a soft, low-swelling 12-month lip filler. Claims that Volbella lasts 18 months confuse it with Vollure.
7. Juvéderm Volbella XC — Infraorbital Hollows / Under-Eye (PMA P110033/S053, May 28, 2021)
- Indication: Deep subcutaneous or supraperiosteal injection to improve the appearance of infraorbital hollows (tear troughs) in adults over 21.
- Clinical Trial Data:
- Month 3 Primary Endpoint: 83.1% responder rate.
- Month 12: 73.4% (69/94) of subjects maintained significant hollow improvement.
- Takeaway: Under-eye Volbella provides up to 12 months of natural tear-trough smoothing. Compare this with RHA Redensity for under-eye hollows and surgical options on under-eye bags vs. blepharoplasty.
8. Juvéderm Ultra XC — Lip Augmentation (PMA P050047/S044, September 30, 2015)
- Indication: Injection into the lips and perioral area for lip augmentation in adults over 21.
- Clinical Trial Data:
- Month 3 Primary Endpoint: 79.1% (110/139) responder rate.
- Month 12: 56.4% (57/101) maintained fullness.
- Takeaway: Ultra XC provides higher water binding and more noticeable volumetric projection than Volbella, lasting 9 to 12 months.
9. Skinvive by Juvéderm — Cheek Smoothness (PMA P110033/S059, May 11, 2023)
- Indication: Intradermal microdroplet injection to improve skin smoothness of the cheeks in adults over 21.
- Clinical Trial Data:
- Month 1: 96.2% (251/261 treated cheeks) were ACSS responders after initial treatment or optional touch-up.
- Month 4: 76.3% (196/257).
- Month 9: 15.7% (39/249) — most cheeks were no longer ACSS responders.
- Takeaway: Skinvive is an intradermal smoothness product, not 24-month Voluma. Manufacturer copy of "up to 6 months" is a ceiling. Later labeling supplements S097 (1 May 2025) and S099 (11 June 2026) are Skinvive labeling rows; neck questions belong on Skinvive neck.
Why Manufacturer "Up To" Claims Differ from Patient Experience
Patients frequently wonder why their filler appears to diminish faster than the clinical trial tables suggest:
[The Three Factors Driving Perceived Filler Duration]
1. Optimal treatment (touch-up) ──► Trials include optional 30-day touch-up; volumes vary by area
2. Baseline deficit and volume ──► One syringe split across two cheeks is not full correction
3. Dynamic vs static anatomy ──► Lip SSEDs stop at 1 year; cheek Voluma tables run to 24 months
- The Touch-Up Effect: In PMA clinical trials, investigators administered an initial injection and performed an optional touch-up 30 days later until complete correction was reached. A patient receiving a single 1.0 mL syringe split across both cheeks has not achieved full clinical correction and will perceive faster fading.
- Early swelling is not the same as duration. Hydrophilic HA can look fuller in the first days. That early change is not a published 15–25% "disappearance" rate.
- Mobility changes the table, not a universal 2× factor. Lip SSEDs are 12-month tables. Midface Voluma is the product with a 24-month cheek curve. Do not import cheek Month 24 onto lips.
Long-Term Maintenance, Migration, and Dissolving Considerations
- The Cumulative Stacking Myth: Re-injecting full syringes every 6 months without assessing residual filler leads to overfilling, pillow-face appearance, and tissue distortion. Learn more about the long-term consequences of years of filler.
- Filler Migration: In the lips and perioral zones, excessive volume or poor injection plane selection can cause filler to migrate above the vermilion border. See our comprehensive guide on filler migration causes and treatments.
- Reversibility with Hyaluronidase: All Juvéderm products are hyaluronic acid and can be dissolved with ovine or recombinant human hyaluronidase (Hylenex). Because Vycross fillers feature a tightly cross-linked polymer network, they often require higher enzyme concentrations and multiple dissolving sessions compared to standard HA fillers. Read our clinical guide to dissolving filler with hyaluronidase.
Questions to Ask Before Receiving Juvéderm
- "Which specific Juvéderm formulation are you injecting, and why is it chosen for this anatomical area?"
Why to ask: Ensures you are receiving an area-optimized product (e.g., Voluma for bone structure, Volbella for delicate smoothing). - "Is your longevity estimate based on a single syringe or on full correction with a 30-day touch-up?"
Why to ask: Aligns expectations with the PMA trial design. - "If I am treating my lips, should I expect 9 to 12 months rather than 18 months?"
Why to ask: Confirms the provider understands the difference between Volbella lips and Vollure folds. - "Do you have ultrasound imaging available in the clinic to verify depth and check for residual filler prior to re-injection?"
Why to ask: Prevents overfilling and ensures safe vascular plane targeting.
Frequently Asked Questions
How long does Juvéderm last in the lips?
Juvéderm Ultra XC and Volbella XC typically last 9 to 12 months in the lips. In FDA trials, 56.4% of Ultra XC patients and 61.8% of Volbella patients maintained fullness at 1 year. Constant mouth movement accelerates breakdown compared to facial bone injections.
How long does Voluma last in the cheeks versus the chin versus the temples?
- Cheeks: Up to 24 months (67.1% responders at 2 years in P110033).
- Temples: Up to 13 months (72.2% GAIS responders at Month 13 in P110033/S070).
- Chin: Up to 12 months (57.6% responders at Month 12 in P110033/S047).
Does Volbella last 18 months?
No. Volbella XC in the lips is FDA-approved with documented duration of up to 12 months. The 18-month duration belongs to Juvéderm Vollure XC when injected into nasolabial folds (P110033/S020).
How often should you get Juvéderm?
Most patients schedule maintenance touch-ups every 9 to 12 months for lips, every 12 to 15 months for nasolabial folds, and every 18 to 24 months for midface cheek volume. Re-injecting too frequently increases the risk of overfilling and filler migration.
Does Juvéderm last longer than Botox?
Yes. Neuromodulators (Botox, Dysport, Xeomin, Jeuveau) work on dynamic muscle contraction and last 3 to 4 months. Dermal fillers physically occupy space in tissue planes and last 6 to 24 months depending on the specific product and area.
Where does Juvéderm go when it wears off?
Hyaluronic acid is gradually broken down by endogenous tissue enzymes (hyaluronidases) and free radicals into simple water and carbon dioxide, which are processed naturally and excreted by the lymphatic and metabolic systems.
Sources
- FDA CDRH — Summary of Safety and Effectiveness Data (SSED) P110033 Original: JUVÉDERM VOLUMA XC Midface Volume Restoration (Approved October 22, 2013): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033B.pdf
- FDA CDRH — SSED P110033/S018: JUVÉDERM VOLBELLA XC Lip Augmentation and Perioral Rhytids (Approved May 31, 2016): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S018B.pdf
- FDA CDRH — SSED P110033/S020: JUVÉDERM VOLLURE XC Nasolabial Folds (Approved March 17, 2017): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S020B.pdf
- FDA CDRH — SSED P110033/S047: JUVÉDERM VOLUMA XC Chin Augmentation (Approved June 12, 2020): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S047B.pdf
- FDA CDRH — SSED P110033/S053: JUVÉDERM VOLBELLA XC Infraorbital Hollows (Approved May 28, 2021): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S053B.pdf
- FDA CDRH — SSED P110033/S059: SKINVIVE by JUVÉDERM Cheek Skin Smoothness (Approved May 11, 2023): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S059B.pdf
- FDA CDRH — SSED P110033/S065: JUVÉDERM VOLUX XC Jawline Definition (Approved July 29, 2022): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S065B.pdf
- FDA CDRH — SSED P110033/S070: JUVÉDERM VOLUMA XC Temple Hollowing (Approved October 6, 2023): https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S070B.pdf
- FDA CDRH — SSED P050047/S044: JUVÉDERM Ultra XC Lip Augmentation (Approved September 30, 2015): https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047S044B.pdf
- FDA CDRH — SSED P050047 Original: JUVÉDERM 24HV, 30, 30HV Dermal Fillers (Approved June 2, 2006): https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047B.pdf
- Electronic Code of Federal Regulations (eCFR) — 21 CFR 878.3540 Absorbable Hyaluronic Acid Dermal Filler (Class III, Product Code LMH): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878/subpart-D/section-878.3540
- American Society of Plastic Surgeons (ASPS) — Dermal Fillers Overview & Duration Guidelines: https://www.plasticsurgery.org/cosmetic-procedures/dermal-fillers
- American Society for Dermatologic Surgery (ASDS) — Hyaluronic Acid Fillers and Safety: https://www.asds.net/skin-experts/skin-treatments/dermal-fillers
